Skip to main content
Fig. 2 | Clinical Epigenetics

Fig. 2

From: Combination treatment strategy for pancreatic cancer involving the novel HDAC inhibitor MPT0E028 with a MEK inhibitor beyond K-Ras status

Fig. 2

Cytotoxic effect of combination SAHA with MEK inhibitors in pancreatic cancer cells. AsPC-1 (a) and PANC-1 (b) cells were treated with DMSO, SAHA, PD98059 (PD), or SAHA plus PD98059 with indicated concentration for 72 h. AsPC-1 (c) and BxPC-3 (d) cells were treated with DMSO, SAHA, trametinib (T), or SAHA plus trametinib with indicated concentration for 72 h. Left panels: Cell viability was determined by MTT assay. Right panels: Combination index (CI) and fraction affected (Fa) are calculated by CompuSyn software. PD 5, PD 10, PD 20, and PD 40 were represented here as PD98059 5 μM, 10 μM, 20 μM and 40 μM.T 0.3, T 1, and T 3 were represented here as trametinib 0.3 nM, 1 nM, and 3 nM

Back to article page